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Summary Fifteen post-menopausal patients with advanced breast cancer were treated with the LH-RH
agonist leuprorelin (D-leu6-des-gly'0-Gn-RH-ethylamide) given in a dosage of 7.5 mg as a monthly sub-
cutaneous depot injection, to assess the clinical activity and endocrine response to treatment. None of the 15
patients showed an objective response to treatment, although four patients had stable disease for at least 6
months. No toxicity was demonstrated. Endocrine effects after 4 weeks' treatment were as follows: mean levels
of serum gonadotrophins fell to 10% of their pretreatment values; there were no significant changes in the
levels of prolactin on treatment; there was a significant decrease in the levels of serum testosterone in 12 out of
14 patients; there were no significant changes in the levels of oestradiol, androstenedione and oestrone. The
lowering of serum testosterone suggests that androgens in post-menopausal women may be partly produced by
the ovaries, stimulated by LH and FSH. This fall in testosterone may explain why some post-menopausal
breast cancer patients in other studies have been reported to respond to treatment with LH-RH agonists, as it
would decrease the substrate for the peripheral synthesis of oestrogens.
Luteinising hormone-releasing hormone (LH-RH) agonists
cause a reduction in the levels of plasma oestrogens in
premenopausal women when given in a continuous, non-
pulsatile manner. This is a result of down-regulation of
pituitary receptors, which causes a decrease in the release of
luteinising hormone, leading to a reduction in ovarian oest-
rogen synthesis (Furr & Milstead, 1988). Several of these
agonists have been used in the treatment of premenopausal
patients with metastatic cancer, with response rates of
30-40% (Klijn et al., 1982; Harvey et al., 1983; Nicholson et
al., 1985), similar to the results with oophorectomy or radi-
ation-induced menopause (Stoll, 1979). More surprisingly,
these agents have also been reputed to be effective in
16-20% of post-menopausal patients with advanced breast
cancer (Harvey et al., 1981; Plowman et al., 1986). It has
been suggested that response in this group may be due to a
direct effect on the tumour, as some LH-RH agonists have
been shown to have an inhibitory effect on breast cancer cells
in vitro (Blankenstein et al., 1985; Miller et al., 1985), and
LH-RH binding sites have been demonstrated in several
breast cancer cell lines (Eidne et al., 1987).
More recently, it has been shown that in post-menopausal
breast cancer patients treated with an LH-RH agonist (goser-
elin), there was a significant reduction of serum testosterone
levels, which was associated with a 22% fall in the level of
serum oestradiol (Dowsett et al., 1988). It is therefore possible
that the response of post-menopausal patients to treatment
with LH-RH analogues may be due to decreased oestrogenic
stimulation, rather than to a direct, inhibitory effect on the
tumour.
In this study, the clinical and endocrine response of 15
post-menopausal patients with advanced breast cancer was
evaluated during their treatment with the LH-RH agonist
leuprorelin (D-leu6-des-gly'0-Gn-RH-ethylamide) (Lederle
Laboratories, Gosport, Hampshire, UK).
Patients and methods
Fifteen post-menopausal women with locally advanced or
metastatic, histologically proven breast cancer were entered
into the study. Informed consent was obtained from all
patients. Their mean age was 66 ± 7.6 years (mean ± s.d.),
range 49-77, the mean weight was 68.5 ± 15.8 kg, range
50.1-108.5, and all patients were at least 2 years post-
menopausal. Two tumours were oestrogen receptor (ER)
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positive, one was ER negative, the receptor status of the
remainder being unknown. The sites of disease are shown in
Table I. After an initial assessment, which included physical
examination, chest X-ray, isotope bone scan, liver ultra-
sound, electrocardiogram and urinalysis, treatment was com-
menced with 7.5 mg of leuprorelin given subcutaneously
every fourth week. The leuprorelin was given as a depot
injection, through a small gauge needle (23G), the drug being
formulated as polylactic/polyglycolic acid microspheres.
Blood samples for full blood count, platelets, urea and
electrolytes, calcium, phosphate, liver function, and levels of
gonadotrophins, oestrone, oestradiol, androstenedione and
testosterone were taken pre-treatment, at weeks 1, 2 and 4,
and thereafter just before each subsequent injection. Chest
X-ray, bone and liver scans were repeated at 3-monthly
intervals, and at suspected relapse. Treatment was discontinued
when there was objective evidence of disease progression
according to the WHO criteria of response (World Health
Organization, 1979).
Five women had received no previous hormone therapy
and 10 had previous treatment with tamoxifen, which in all
cases had been stopped at least 4 weeks before commencing
the leuprorelin therapy. No patients had received any other
endocrine therapy. Two women had also previously received
chemotherapy (melphalan and 5-fluoro-uracil, and metho-
trexate, mitoxantrone and mitomycin C). Of the women who
had received therapy with tamoxifen, the mean length of time
to progression was 17.7 ± 14.1 (± s.d.) months, with a range
of 6-54 months. Three out of the 10 patients had shown an
initial partial response to tamoxifen but had subsequently
relapsed on treatment.
Hormone measurements
Serum samples were stored at - 20C and assayed in batches
for luteinising hormone (LH), follicle stimulating hormone
(FSH), prolactin (Prl), oestradiol (E2), oestrone (El),
androstenedione (M'A) and testosterone (T) by radioimmuno-
assay techniques which have been described previously
Table I Disease sites in 15 post-menopausal breast cancer patients
undergoing treatment with leuprorelin
Disease site Number
Breast 9
Soft tissue/nodes 8
Bone 5
Liver 2
Lung 3
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(Ferguson et al., 1982; Dowsett et al., 1983, 1984, 1987a;
Harris et al., 1982, 1983). All samples from the same patient
were analysed in the same batch. The intra- and inter-assay
coefficients of variation were < 10% and < 15% respectively
for all analytes.
Statistical analyses
The results were considered as percentages of pretreatment
values, then a logarithmic transformation was taken on the
data to normalise the distribution. The percentages were
compared to 100% using paired t tests. The geometric mean
percentages with 95% confidence limits are given in Figure 2.
The geometric mean percentages with P values for week, 4, 8
and 12 are given in Table III. Multiple testing has been
performed and a significance level lower than 5% should be
considered. However, P values up to 10% are shown in
Table III for extra information. The mean serum hormone
levels before and after 4 weeks treatment are shown in Table
IV.
Results
Clinical
Response to treatment was determined according to standard
WHO criteria for response. None of the patients showed an
objective response to treatment. Four patients had stable
disease for more than 24 weeks. One of these remains stable
at 40 weeks. One patient who was disease stable at 24 weeks
discontinued treatment with leuprorelin and had a course of
radiotherapy to her localised breast carcinoma. The other
two patients who initially had stable disease, showed progres-
sion after 24 weeks. Of the 13 patients who progressed on
treatment (including the latter two), the mean time to pro-
gression was 15.8 ± 12.9 ( ± s.d.) weeks, range 2-40 weeks.
Time to progression is demonstrated in Figure 1.
Subsequent treatment, and the best response to this is
summarised in Table II.
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Toxicity
None of the fifteen patients treated with leuprorelin reported
any significant adverse reaction to the therapy and, in partic-
ular, there were no hot flushes or irritation at the site of
injection. There were no observed haematological or bio-
chemical abnormalities.
Endocrine results
The effect of leuprorelin on the levels of LH, FSH, Prl, T,
A4A, E2, and El during the first 24 weeks of therapy are
shown in Figure 2 as a percentage of the pretreatment value
(geometric means and 95% confidence intervals). The arith-
metic mean serum hormone levels before and after 4 weeks'
treatment are shown in Table III. The most marked changes
are seen in the levels of LH and FSH. LH levels fell to
63.4% of the pretreatment level at week 1, 28.5% at week 2
and 8.7% at week 4. Thereafter, they ranged between 6.2%
and 10.2% of pretreatment levels. FSH fell more rapidly, to
30% of the pretreatment level at week 1, 10.3% at week 2
and 4.9% at week 4. Thereafter they varied between 5.8%
and 14.5% of the pretreatment level. Five patients had pre-
treatment FSH levels which were less than 20 IU 1'. How-
ever, all five patients were aged over 60 years, and these low
levels probably reflect the decreased gonadotrophin secretion
associated with advanced menopause.
Serum Prl levels showed no significant changes, although
three individual patients showed marked increases in Prl
levels to above 500 mIU 1` at the time of their disease
progression.
Mean serum T levels fell significantly during treatment, to
74.1% of pretreatment levels at 4 weeks. Thereafter, the levels
remained lower than the pretreatment levels at all time
points. After 4 weeks' therapy, 12 out of the 14 patients on
whom we had paired samples showed a lowering of their
testerone levels (Figure 3), this being most marked in the
patients whose pretreatment levels were greater than
1.5 nmol-'. In these seven patients, levels fell from
2.09 ± 0.46 nmol 1' (mean ± s.d.) to 1.30 ± 0.43 nmol [1-'. In
the seven patients with baseline levels less than 1.5 nmol 1-',
the levels fell from 1.25 ± 0.17 nmol 1' to
1.16 ± 0.27 nmol 1-'. In two patients, the serum testosterone
levels showed a slight rise at 4 weeks. Mean M4A levels were
also lower than the pretreatment levels for the first 4 weeks
of therapy, but thereafter ranged between 87.3% and 132%
of pretreatment levels.
E2 levels fell to 85.6% of the pretreatment value at week 4,
and thereafter varied between 82.9% and 116% of pretreat-
ment levels. In nine out of 14 patients, E2 levels fell after 4
weeks' therapy, in three patients levels increased and in two
patients they remained unchanged (Figure 3). These changes
were not as marked as the changes in the testosterone levels;
statistical significance was approached only after 4 weeks.
One patient had a pretreatment and on treatment level of
> 100 pmol 1'. This patient was the heaviest patient in the
study (108.5 kg), and also had the highest level of El. Mean
El levels fell to 85.0% of the pretreatment levels at 4 weeks,
and thereafter ranged between 76.3% and 102.1% of the
pretreatment levels.
Figure 1 Actual time to progression in 14 post-menopausal
breast cancer patients treated with leuprorelin. One patient was
excluded who remained in stable disease at 6 months, and then
had a course of radiotherapy.
Table II Treatment following therapy with leuprorelin, and the best
response to this therapy
Aromatase
Response MPA Tamoxifen inhibitor Chemotherapy
PR I 1 2
NC 1 3 2
PD I I
Discussion
In this study, none of our 15 patients showed an objective
response to treatment with the LH-RH agonist, leuprorelin.
This would correspond with a < 5% chance of there being a
>20% response rate. Thus our response rate was lower but
not inconsistent with the earlier findings of Harvey et al.
(1981), Plowman et al. (1986) and Harris et al. (1988a), who
showed, respectively, a 16%, 20% and 11% partial response
rate to therapy with an LH-RH agonist in post-menopausal
breast cancer patients. In addition, in our study, four out of
15 patients had stable disease for at least 6 months, which
may have been of value for those patients. While it would be646 I.L. CRIGHTON et al.
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Figure 2 Mean changes in levels of LH, FSH, T, A4A, E2 and El during leuprorelin therapy. Values are given as geometric
means and 95% confidence limits. The number of patients was 15 on weeks 0, 1 and 2; 14 on week 4; 12 on week 8; 9 on week 12;
7 on week 16; 5 on week 20; 4 on week 24. The P values at weeks 4, 8 and 12 are given in Table 111.
Table III Geometric means of hormone levels, as a percentage of
initial value, in post-menopausal patients with breast cancer at 4, 8 and
12 weeks after first treatment with leuprorelin
Hormone
LH
FSH
Prl
T
A4A
E2
El
Week 4
8.7%
P<0.00O
(n= 14)
4.9%
P<0.00O
(n= 14)
123.5%
n.s.
(n= 14)
74.1%
P<0.002
(n= 14)
96.4%
n.s.
(n= 14)
85.6%
0.05 <P<0.10
(n= 14)
85.0%
P<0.02
(n= 14)
Week 8
6.3%
P<0.00O
(n= 12)
5.8%
P<0.001
(n= 12)
100.9%
n.s.
(n= 12)
79.9%
P<0.05
(n= 12)
132.5%
n.s.
(n= 12)
96.9%
n.s.
(n= 12)
102.1%
n.s.
(n= 12)
Week 12
7.0%
P<0.001
(n = 9)
8.0%
P<0.001
(n = 9)
123.1%
n.s.
(n = 9)
72.8%
P<0.005
(n = 9)
101.8%
n.s.
(n = 9)
116.2%
n.s.
(n = 9)
99.9%
n.s.
(n = 9)
The percentages were compared to 100% using paired t tests, after
performing a logarithmic transformation.
biologically of interest to perform a larger study to define
more precisely the response rate to these agents in post-
menopausal patients this would be difficult to justify in cir-
cumstances where there are other clearly more effective
agents from which to choose.
Endocrine measurements have confirmed that leuproreliin
is a potent suppressor of LH and FSH levels, with a >90%
fall in serum levels after 4 weeks, which was maintained for
as long as therapy was continued. We have also demon-
strated that leuprorelin causes a significant lowering of serum
testosterone levels, particularly in those patients with pre-
treatment levels of greater than 1.5 nmol 1-'. This confirms
the findings of Dowsett et al. (1988) in goserelin-treated
patients, and would support the suggestion that androgens in
post-menopausal women may partly be produced by the
ovaries, under the stimulation of pituitary gonadotrophins.
There was a 15% drop in serum E2 levels after four weeks
treatment, but this was of only borderline statistical
significance (0.05 < P<0.10), and was not sustained con-
sistently, nor was any lowering of E2 levels associated with
any lengthening of the time to progression of the disease.
Although there are differences between the current study and
that on goserelin treatment in the magnitude and statistical
significance of the changes in plasma steroid hormone levels,
the two studies are largely consistent in their indication of an
ovarian suppressant effect of LHRH agonists in post-meno-
pausal women which results in a relatively modest suppres-
sion of circulating androgen and oestrogen levels. These
differences between the studies probably reflect the within-
patient variability of the four steroids (Lonning et al., 1989)
and the between-patient variability in the endocrine response
to LHRH agonist treatment.
One other interesting endocrine observation was that in
three patients, serum prolactin levels rose markedly at the
time of progression (from levels of 100, 110 and 130 mlU 1-',
to 1300, 560 and 670 mlU I-', respectively). This has pre-
viously been noted in patients progressing on other hormonal
and cytotoxic treatments (Holtkamp et al., 1984; Dowsett et
al., 1987b). It is probable that this is a result of, rather than a
cause of, the disease progression.
In conclusion, leuprorelin in our hands was largely
ineffective as a single agent therapy for the treatment of
post-menopausal breast cancer. However, in 12 out of 14
patients, there was a decrease in the levels of serum tes-
tosterone, and, since androgens are a substrate for the
peripheral production of oestrogens (Grodin et al., 1973), it
may be that combination endocrine therapy with an LH-RH
agonist (to decrease the substrate for peripheral oestrogen
synthesis), and an aromatase inhibitor (to suppress conver-
sion of the substrate) would be more effective than treatment
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Figure 3 Individual changes in serum testosterone and serum oestradiol in 14 post-menopausal patients with breast cancer before
(Base) and after 4 weeks' therapy with leuprorelin. The lines connect the values in the same patient.
Table IV Mean hormone levels in post-menopausal patients with breast cancer before
and four weeks after first treatment with leuprorelin
Pretreatment After 4 weeks
Hormone (n = 15) (n = 14)
LH (IU 1-') 50.8 ± 16.2 (5-210) 2.7 + 0.3 (1.8-5.6)
FSH (IU 1-') 51.3 10.8 (10-160) 3.5 0.8 (0.8-10)
PrI (mlU 1`) 143.3 ± 18.8 (90-350) 207.1 ± 51.5 (90-730)
T (nmol I`) 1.65 0.14 (1.0-2.8) 1.23 0.1 (0.8-2.1)
A4A (nmol 1`) 2.57 ± 0.29 (0.6-4.6) 2.34 ± 0.29 (0.9-5.1)
E2 (pmol 1') 35.8 ± 8.3 (12-130) 34.2 ± 8.3 (6-120)
El (pmol ') 162.7± 27.3 (70-490) 135.8 18.5 (50-310)
Arithmetic mean ± s.e.m. (range).
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